News Release Detail
Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
Mylan CEO
Mylan Institutional president,
Previously, the only available version of Levetiracetam for Injection came in a vial presentation, 500 mg/5 mL. This product had U.S. sales of approximately
This press release includes statement that may constitute "forward-looking statements" (including with regard to product launches and the company's strategies) as well as other information that is necessarily subject to risks, uncertainties and assumptions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, market acceptance of the company's products, the impact of competition and the other risks detailed in the company's filings with the
(1) Levetiracetam in Sodium Chloride Injection for Intravenous Use is an antiepileptic drug indicated for adults (16 years and older) with the following seizure types when oral administration is temporarily not feasible: Partial onset seizures; Myoclonic seizures in patients with juvenile myoclonic epilepsy; Primary generalized tonic-clonic seizures. Safety Information includes: Neuropsychiatric adverse reactions, including: 1) somnolence and fatigue (including asthenia, dizziness), 2) coordination difficulties, and 3) behavioral abnormalities (e.g., psychotic symptoms, suicide ideation, and less than or equal to 5% depression, nervousness, anxiety, emotional lability and other abnormalities); infection. Patients should be monitored for neuropsychiatric signs and symptoms. Withdrawal Seizures: Levetiracetam should be gradually withdrawn. Hematological abnormalities have been noted.
Please see full prescribing information available at www.premixedleve.com for warnings, precautions, adverse reactions and other risk information.
SOURCE
News Provided by Acquire Media